Over the last decade, Antibody Drug Conjugates (ADCs) have
gained a great success due to their documented clinical efficacy and manageable
toxicity. Generally the word “drug” is associated with a chemotherapeutic
drug, however “drug” can also be associated with other cytotoxic
payloads such as radionuclides, termed more specifically, Antibody
Radionuclide Conjugates (ARCs) for radioimmunotherapy (RIT).
A large number of clinical studies have evaluated both ADCs and ARCs
in varied indications. This review collected the clinical results of 11 studies
including 598 patients treated with 6 ADCs and 9 studies including
377 patients treated with 5 ARCs. Toxicity was generally less frequent
with ADCs than with ARCs but often led to more uncomfortable side effects.
Hematological toxicity was higher with ARCs than with ADCs regardless of the radionuclide
used (90Y, 131I or 177Lu).
For radiosensitive hematological malignancies overall response rates varied from 7 to 86%
(median: 50%) with ADCs and from 31 to 95% (median: 83%) with ARCs. Two studies
including 135 patients were performed with ARCs in the most favorable situation of frontline
therapy which can favor global efficacy. Median progression free survival (PFS) varied
between 5.6 and 13.3 months (median: 7.8) with ADCs and between 6 and 25.9 months
(median: 9.4) with ARCs, once again focusing on the most favorable situation of ARCs in
frontline therapy. For solid tumors overall response rates varied from 6 to 34.5% (median:
15%) with ADCs and from 8 to 15% (median: 7.5%) with ARCs.
Both ADCs and ARCs have shown clinical efficacy with acceptable and manageable